Showing 3561-3570 of 7247 results for "".
- L'Oreal Paris Partners with Melanoma Research Alliancehttps://practicaldermatology.com/news/20130520-loreal_paris_partners_with_melanoma_research_alliance/2459539/L'Oreal Paris formed an alliance with the Melanoma Research Alliance (MRA). Over the next three years, L'Oreal Paris will donate over $750,000 to the MRA to fund the new L'Oreal Paris-MRA Team Science Award, led by internationally renowned cancer researcher Dr. Meenhard Herlyn, to research ways to h
- Revealed: Why Skin Feels “Tight” After Using a Facial Cleanserhttps://practicaldermatology.com/news/revealed-why-skin-feels-tight-after-using-a-facial-cleanser/2462023/Some cleansers make the skin feel “tight” and some moisturizers make the skin feel “soft,” but exactly why this occurs hasn't been fully understood. To find out, Reinhold H. Dauskardt, the Ruth G. and William K. Bowes Professor in Stanford’s
- Study Links Vitiligo to Higher Autoimmune and Infection Burden in US Cohorthttps://practicaldermatology.com/news/vitiligo-linked-to-higher-autoimmune-and-infection-burden-in-us-cohort/2486572/New data from a large retrospective study suggested patients with vitiligo experience higher rates of several comorbidities and safety events compared with matched controls. Investigators analyzed Optum Market Clarity EHR dat
- Nail Psoriasis and Real-World Data Highlight Tildrakizumab’s Staying Powerhttps://practicaldermatology.com/news/nail-psoriasis-and-real-world-data-highlight-tildrakizumabs-staying-power/2486482/Two posters presented at the American Academy of Dermatology (AAD) Annual Meeting highlight both clinical trial efficacy and real-world durability of tildrakizumab, an interleukin (IL)-23 p19 inhibitor, in patients with moderate-to-severe plaque psoriasis.
- Study: Elevated Obstetric Risks in Women With Hidradenitis Suppurativahttps://practicaldermatology.com/news/study-finds-elevated-obstetric-risks-in-women-with-hidradenitis-suppurativa/2486444/Women with hidradenitis suppurativa (HS) had significantly higher odds of hypertensive disorders (OR = 1.81), cesarean delivery (OR = 1.34), and preterm birth (OR = 1.20) compared with those without HS, according to a systematic review and meta-analysis presented a
- Transcriptomic Study Identifies IL-1β Axis in Hidradenitis Suppurativahttps://practicaldermatology.com/news/transcriptomic-study-identifies-il-1b-axis-in-hidradenitis-suppurativa/2486448/Comprehensive transcriptomic profiling of hidradenitis suppurativa (HS) highlights a dominant macrophage-derived IL-1β/NLRP3 inflammasome axis, p
- Abrocitinib Shows Efficacy in Chronic Hand Eczema in Phase II Trialhttps://practicaldermatology.com/news/abrocitinib-shows-efficacy-in-chronic-hand-eczema-in-phase-ii-trial/2486424/Abrocitinib, an oral Janus kinase 1 (JAK1) inhibitor approved for atopic dermatitis, demonstrated significant efficacy in patients with chronic hand eczema (CHE) of diverse etiologies in a Phase II randomized trial presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting.
- Povorcitinib Shows Durable Efficacy in HS in Phase 3 STOP-HS Trialshttps://practicaldermatology.com/news/povorcitinib-shows-durable-efficacy-in-hs-in-phase-3-stop-hs-trials/2486420/Late-breaking results from the Phase 3 STOP-HS1 and STOP-HS2 trials presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting showed that povorcitinib, an oral JAK1-selective inhibitor, achieved sustained efficacy and a manageable safety profile through 54 weeks in patients with
- What New Secukinumab Data Mean for HS Patients: A Q&A with Dr. April Armstronghttps://practicaldermatology.com/news/what-new-secukinumab-data-mean-for-hs-patients-a-qa-with-dr-april-armstrong/2486412/In the following Q&A, Dr. April Armstrong, professor and chief of dermatology at UCLA and a study coauthor, talks with Practical Dermatology about the importance of new secukinumab data for patients with hidradenitis suppurativa (HS). Speaking on UCB's recently announced top
- Study: Dermatologists Rarely Prescribe GLP-1 Agents in Psoriasis, HS Cohorthttps://practicaldermatology.com/news/study-dermatologists-rarely-prescribe-glp-1-agents-in-psoriasis-hs-cohort/2486411/A new retrospective review identified a significant gap in care between eligibility for glucagon-like peptide-1 receptor agonists (GLP-1RAs) and real-world utilization among patients with psoriasis and hidradenitis suppurativa (HS).